The effect of ranolazine on the vasodilatorinduced myocardial perfusion abnormality

Journal of Nuclear Cardiology

Volumn 18, Issue 3, 2011, Pages 456-462

  Venkataraman, Rajesh ^a   Aljaroudi, Wael ^a   Belardinelli, Luiz ^b   Heo, Jaekyeong ^a   Iskandrian, Ami E ^a  

^a University of Alabama at Birmingham   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

Coronary artery disease; Myocardial perfusion imaging; Ranolazine; Vasodilator stress testing

Indexed keywords

RANOLAZINE; SODIUM CHANNEL; VASODILATOR AGENT; ACETANILIDE DERIVATIVE; DIAGNOSTIC AGENT; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; MALE; MYOCARDIAL PERFUSION IMAGING; OPEN STUDY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; EXERCISE TEST; LABORATORY DIAGNOSIS; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ACETANILIDES; ENZYME INHIBITORS; EXERCISE TEST; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; PIPERAZINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 79960406156     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-011-9364-1     Document Type: Article

References (24)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146.
2. Zoghbi GJ, Dorfman TA, Iskandrian AE. The effects of medications on myocardial perfusion. J Am Coll Cardiol 2008;52:401-16. (Pubitemid 352040813)
3. Allely MC, Alps BJ. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol 1990;99:5-6. (Pubitemid 20033773)
4. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazine. Heart 2006;92:6-14.
5. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 2004;291:309-16. (Pubitemid 38101603)
6. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82. (Pubitemid 38496341)
7. Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clana-chan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 2006;41:1031-8. (Pubitemid 44791334)
8. Hale SL, Leeka JA, Kloner RA. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J Pharmacol Exp Ther 2006;318:418-23.
9. Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 2008;44:954-67.
10. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007;49:1027-34. (Pubitemid 46349506)
11. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566-75. (Pubitemid 44093970)
12. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol 2001;418:105-10. (Pubitemid 32378816)
13. Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging 2009;2:1301-9.
14. Al Jaroudi W, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.
15. Iskandrian AE, Garcia EV. Nuclear cardiac imaging: principles and applications. 4th ed. Oxford: Oxford University Press; 2008.
16. Mahmarian JJ, Cerqueira MD, Iskandrian AE, et al. Regadenoson induces comparable left ventricular perfusion defects as adeno-sine: A quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009;2:959-68.
17. Berecki G, Zegers JG, Bhuiyan ZA, Verkerk AO, Wilders R, van Ginneken AC. Long-QT syndrome-related sodium channel mutations probed by the dynamic action potential clamp technique. J Physiol 2006;570:237-50.
18. Kunze DL, Lacerda AE, Wilson DL, Brown AM. Cardiac Na currents and the inactivating, reopening, and waiting properties of single cardiac Na channels. J Gen Physiol 1985;86:691-719. (Pubitemid 16205743)
19. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium current". Pharmacol Ther 2008;119:326-39.
20. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005;95:311-6. (Pubitemid 40164531)
21. Stone PH, Chaitman BR, Stocke K, Sano J, DeVault A, Koch GG. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol 2010;56:934-42.
22. Iskandrian AE, Heo J, Mehta D, et al. Gated SPECT perfusion imaging for the simultaneous assessment of myocardial perfusion and ventricular function in the BARI 2D trial: An initial report from the Nuclear Core Laboratory. J Nucl Cardiol 2006;13:83-90. (Pubitemid 43192733)
23. Mahmarian JJ, Dakik HA, Filipchuk NG, et al. An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol 2006;48:2458-67. (Pubitemid 44881230)
24. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-91. (Pubitemid 351365675)